on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
Heights Capital Management exceeds 5% stake in GenSight Biologics
On January 9, 2025, Heights Capital Management announced that it had crossed upwards the thresholds of 5% of the capital and voting rights of GenSight Biologics. On November 1, 2024, the company held 7,574,746 shares, or 7.03% of the capital. This increase is the result of the subscription to renewed capital.
As of January 8, 2025, Heights Capital Management holds 12,008,310 shares, representing 9.62% of the capital and voting rights. In addition, the company holds stock warrants and convertible bonds, which may lead to a further increase in its stake.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news